View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar, Belgyógyászati Intézet, Hematológiai Tanszék, Debrecen, Nagyerdei krt. 98., 4032

Összefoglaló. A Bruton-féle tirozin-kinázt gátló ibrutinib és a B-sejtes lymphoma-2-t gátló venetoklax a krónikus lymphoid leukaemia (CLL) kezelésének egyre korábbi vonalában alkalmazható, és ezek mellett a progressziómentes túlélés növekedése figyelhető meg. A célzott kismolekulákkal végzett kezelés nemcsak a CLL lefolyását, de a betegek gondozását is alapvetően megváltoztatta. A tartósan adagolt orális szerek mellett a betegek nagyobb valószínűséggel jelennek meg a panaszaiknak megfelelő szakrendeléseken. Az új típusú szerek hatásai és mellékhatásai mellett az alapvető gyógyszer-interakciókra is fel kell hívni a figyelmet. Kiemelt fontosságú az ibrutinib hypertoniát provokáló hatása, illetve a 6–16%-ban megjelenő pitvarfibrilláció. Ez utóbbi ellátását a gyógyszer-interakciókon túl az ibrutinib vérzékenységet okozó hatása is nehezíti. A CLL-lel, illetve annak kezelésével kapcsolatos ismeretek a másodlagos daganatok, néhány gastrointestinalis és bőrgyógyászati betegség megközelítése szempontjából is fontosak. A venetoklax mellett potenciálisan kialakuló tumorlízis-szindróma alkalmanként a nefrológusok bevonását igényli. A betegek gondozása, megfelelő szakszerű ellátása és a betegutak optimalizálása érdekében a háziorvosok, a sürgősségi ellátók és az egyéb szakellátó helyek szoros együttműködése szükséges szakorvosi konzultáció keretei között. Orv Hetil. 2021; 162(9): 336–343.

Summary. Chronic lymphocytic leukemia (CLL) is ubiquitously treated with novel agents. The Bruton’s tyrosine kinase inhibitor ibrutinib and the B-cell lymphoma 2 inhibitor venetoclax can be used increasingly in earlier lines of treatment with improved progression-free survival. Treatment with targeted small molecules fundamentally changed not only the course of CLL but also the care of patients. With the administration of long-term oral medications, patients are more likely to show up at specialist clinics that match their complaints. In addition to the effects and side effects of the new drugs, attention should also be drawn to basic drug interactions. The effect of ibrutinib on blood pressure and the ability to provoke atrial fibrillation in 6–16% of cases are of paramount importance. In addition to drug interactions, the treatment of the latter is also complicated by the hemorrhagic effect of ibrutinib. Knowledge on CLL and its treatment is also important in the approach to secondary tumors, some gastrointestinal and dermatological diseases. The potential for tumor lysis syndrome of venetoclax requires close collaboration with nephrologists. In order to provide appropriate professional care and optimize patient pathways, close co-operation between GPs, emergency care providers and other specialist care facilities is required within the framework of professional consultation. Orv Hetil. 2021; 162(9): 336–343.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724–3734. [Erratum: Blood 2011; 117: 3477.]

  • 2

    Hernández JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995; 75(1 Suppl): 381–394.

  • 3

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70: 7–30.

  • 4

    Gurbity Pálfi T, Fésüs V, Bödör C, et al. State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies. [A krónikus lymphocytás leukaemia korszerű molekuláris diagnosztikája és kezelése az új célzott terápiák korszakában.] Orv Hetil. 2017; 158: 1620–1629. [Hungarian]

  • 5

    Farooqui M, Valdez J, Soto S, et al. Atrial fibrillation in CLL/SLL patients on ibrutinib. Blood 2015; 126: 2933–2933.

  • 6

    Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373: 2425–2437.

  • 7

    Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213–223.

  • 8

    McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K–Akt signaling. Blood 2014; 124: 3829–3830.

  • 9

    McMullen JR, Amirahmadi F, Woodcock EA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 2007; 104: 612–617.

  • 10

    Ezeani M, Elom S. Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia. Open Heart 2017; 4: e000596.

  • 11

    Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018; 4: 1491–1500.

  • 12

    Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017; 15: 835–847.

  • 13

    Kazianka L, Drucker C, Skrabs C, et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia 2017; 31: 1117–1122.

  • 14

    Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2015; 29: 783–787.

  • 15

    Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 2014; 124: 3991–3995.

  • 16

    Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126: 739–745.

  • 17

    Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016; 387: 2605–2613.

  • 18

    Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125: 2497–2506.

  • 19

    Chai-Adisaksopha C, Crowther M, Isayama T, et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124: 2450–2458.

  • 20

    Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016; 41: 206–232.

  • 21

    Suzuki T, Miyakoshi S, Nanba A, et al. A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment. J Clin Exp Hematop. 2018; 58: 136–140.

  • 22

    Arkkila PE, Nuutinen H, Ebeling F, et al. Colonic involvement in a patient with chronic lymphocytic leukaemia. Gastroenterol Res Pract. 2008; 2008: 742146.

  • 23

    Green M, Abuamr KM. Chronic lymphocytic leukemia manifesting as colon polyps. Program No. P1543. ACG 2018 Annual Scientific Meeting Abstracts. American College of Gastroenterology, Philadelphia, PA. Am J Gastroenterol. 2018; 113(Suppl 1): 888.

  • 24

    Weidner A-S, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015; 39: 1661–1667.

  • 25

    de Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2015; 75: 907–916.

  • 26

    de Jong J, Hellemans P, Jiao J, et al. An open-label, sequential-design drug interaction study of the effects of omeprazole on the pharmacokinetics of ibrutinib in healthy adults. Blood 2016; 128: 1588.

  • 27

    Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131: 2745–2760.

  • 28

    Falchi L, Vitale C, Keating MJ, et al. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol. 2016; 27: 1100–1106.

  • 29

    Parry HM, Mirajkar N, Cutmore N, et al. Long-term ibrutinib therapy reverses CD8+ T cell exhaustion in B cell chronic lymphocytic leukaemia. Front Immunol. 2019; 10: 2832.

  • 30

    Szerafin L, Jakó J, Varju L. Occurrence of associated tumours in chronic lymphocytic leukaemia. [Társult tumorok előfordulása krónikus lymphoid leukaemiában.] Orv Hetil. 2016; 157: 1752–1756. [Hungarian]

  • 31

    Whittle JR, Vaillant F, Surgenor E, et al. Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer. Clin Cancer Res. 2020; 26: 4120–4134.

  • 32

    Lochmann TL, Floros KV, Naseri M, et al. Venetoclax is effective in small-cell lung cancers with high BCL-2 expression. Clin Cancer Res. 2018; 24: 360–369.

  • 33

    Archibald WJ, Meacham PJ, Williams AM, et al. Management of melanoma in patients with chronic lymphocytic leukemia. Leuk Res. 2018; 71: 43–46.

  • 34

    Ishdorj G, Beiggi S, Nugent Z, et al. Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leuk Lymphoma 2019; 60: 3204–3213.

  • 35

    Rhodes JM, LoRe VA 3rd, Mato AR, et al. Ibrutinib-associated arthralgias/myalgias in patients with chronic lymphocytic leukemia: incidence and impact on clinical outcomes. Clin Lymphoma Myeloma Leuk. 2020; 20: 438–444.e1.

  • 36

    Poitou-Verkinder AL, Francois A, Drieux F, et al. The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma: a 25-year multicenter experience. PLoS ONE 2015; 10: e0119156.

  • 37

    Edrees F, Black RM, Leb L, et al. Minimal change disease: a case report of an unusual relationship. Saudi J Kidney Dis Transpl. 2016; 27: 816–820.

  • 38

    Soldarini M, Farina L, Genderini A, et al. A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome. BMJ Case Rep. 2017; 2017: bcr-2016-218850.

  • 39

    Anastasopoulou A, DiPippo AJ, Kontoyiannis DP. Non-Aspergillus invasive mould infections in patients treated with ibrutinib. Mycoses 2020; 63: 787–793.

  • 40

    Mangla A, Khare A, Vineeth V, et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 2004; 104: 1191–1197.

  • 41

    Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 2015; 126: 2213–2219. [Erratum: Blood 2016; 128: 1020.]

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Oct 2020 0 0 0
Nov 2020 0 0 0
Dec 2020 0 0 0
Jan 2021 0 0 0
Feb 2021 0 2 3
Mar 2021 0 99 123
Apr 2021 0 25 41